Table 1.
Patient’s characteristics.
| Age, years | |
| Mean | 67 |
| Range | 44–88 |
| Sex, n.(%) | |
| Male | 46 (64%) |
| Female | 26 (36%) |
| Line of therapy | |
| 1st | 72 (100%) |
| Treatment received | |
| CT plus Bev CT alone |
50 (69%) 22 (31%) |
| Location of primary tumor | |
| Left | 48 (66%) |
| Right | 24 (34%) |
| Site of metastasis | |
| Single organ | 26 (36%) |
| Multi-organ | 46 (64%) |
| Liver | 62 (86%) |
| Peritoneum | 12 (17%) |
| Lymph-node | 10 (14%) |
| Lung | 6 (8%) |
| Histology | |
| Adenocarcinoma | 72 (100%) |
| RAS tissue/plasma baseline | |
| Mutated KRAS G12D KRAS G12V KRAS G12A KRAS G12R/S KRAS G12C KRAS Q61 KRAS A146T KRAS G13D NRAS G12D NRAS G12C NRAS Q61R NRAS A146T BRAF V600E |
72(100%) 19 (26%) 16 (22%) 5 (7%) 2 (3%) 6 (8%) 5 (7%) 5 (7%) 7 (10%) 3 (4%) 1(1%) 1 (1%) 1(1%) 1(1%) |
CT: chemotherapy; Bev: Bevacizumab.